NASDAQ:RXST

RxSight (RXST) Stock Forecast, Price & News

$26.75

-1.14 (-4.09%)

(As of 10/2/2023 ET)

Compare

Today's Range: $26.62
▼
$27.90
50-Day Range: $26.75
▼
$33.37
52-Week Range: $9.78
▼
$33.77

Volume: 264,382 shs
Average Volume: 425,006 shs
Market Capitalization: $953.37 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $30.50

RxSight MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 14.0% Upside
$30.50 Price Target
Short Interest: Healthy
3.79% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.96
Based on 3 Articles This Week
Insider Trading: Selling Shares
$1.84 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.66) to ($1.46) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

364th out of 975 stocks

Ophthalmic Goods Industry

6th out of 7 stocks

2.4

Analyst's Opinion

Consensus Rating
RxSight has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $30.50, RxSight has a forecasted upside of 14.0% from its current price of $26.75.
Amount of Analyst Coverage
RxSight has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
3.79% of the float of RxSight has been sold short.
Short Interest Ratio / Days to Cover
RxSight has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in RxSight has recently decreased by 24.82%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
RxSight does not currently pay a dividend.
Dividend Growth
RxSight does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RXST.

2.8

News and Social Media Coverage

News Sentiment
RxSight has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for RxSight this week, compared to 1 article on an average week.
Search Interest
Only 5 people have searched for RXST on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added RxSight to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, RxSight insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,839,683.00 in company stock.
Percentage Held by Insiders
21.13% of the stock of RxSight is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
66.51% of the stock of RxSight is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for RxSight are expected to grow in the coming year, from ($1.66) to ($1.46) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of RxSight is -13.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of RxSight is -13.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
RxSight has a P/B Ratio of 8.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About RxSight (NASDAQ:RXST) Stock

RxSight, Inc., an ophthalmic medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

RXST Price History

30 days | 90 days | 365 days | Advanced Chart

RXST Stock News Headlines

September 27, 2023 | americanbankingnews.com

Head-To-Head Survey: RxSight (NASDAQ:RXST) and Signature Eyewear (OTCMKTS:SEYE)

September 7, 2023 | finance.yahoo.com

RxSight, Inc. (RXST) Crossed Above the 20-Day Moving Average: What That Means for Investors

October 3, 2023 | Wall Street Fundamentals (Ad)

The "Plug and Play" Model Putting Online Giants to Shame

While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."

August 24, 2023 | finance.yahoo.com

RxSight, Inc. (RXST) Interactive Stock Chart - Yahoo Finance

August 18, 2023 | fool.com

RxSight (NASDAQ: RXST)

August 16, 2023 | msn.com

RxSight: Poised To Make Waves In Ophthalmic Market

August 14, 2023 | finance.yahoo.com

With 40% ownership, RxSight, Inc. (NASDAQ:RXST) has piqued the interest of institutional investors

August 12, 2023 | markets.businessinsider.com

J.P. Morgan Sticks to Their Buy Rating for RxSight (RXST)

October 3, 2023 | Wall Street Fundamentals (Ad)

The "Plug and Play" Model Putting Online Giants to Shame

August 8, 2023 | msn.com

Oppenheimer Maintains RxSight (RXST) Outperform Recommendation

August 8, 2023 | msn.com

Needham Reiterates RxSight (RXST) Buy Recommendation

August 8, 2023 | markets.businessinsider.com

Where RxSight Stands With Analysts

August 8, 2023 | finance.yahoo.com

RxSight, Inc. (NASDAQ:RXST) Q2 2023 Earnings Call Transcript

August 4, 2023 | benzinga.com

RxSight's Earnings: A Preview

August 3, 2023 | msn.com

RxSight (RXST) Price Target Increased by 11.03% to 30.80

July 27, 2023 | finance.yahoo.com

RxSight, Inc. to Report Second Quarter Financial Results on August 7, 2023

July 12, 2023 | markets.businessinsider.com

RxSight Is A Potential Acquisition Target: Analyst Highlights How LAL Revenue Mix Could Drive Share Price To $45+

July 12, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for RxSight

July 6, 2023 | msn.com

RxSight (RXST) Price Target Increased by 16.24% to 27.74

June 18, 2023 | finance.yahoo.com

Investors in RxSight (NASDAQ:RXST) have seen respectable returns of 79% over the past year

June 6, 2023 | msn.com

BTIG Maintains RxSight (RXST) Buy Recommendation

May 16, 2023 | seekingalpha.com

RxSight: Improved Margin Outlook

May 12, 2023 | msn.com

Wells Fargo Maintains RxSight (RXST) Equal-Weight Recommendation

May 9, 2023 | markets.businessinsider.com

BTIG Keeps Their Buy Rating on RxSight (RXST)

May 9, 2023 | finance.yahoo.com

RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates

May 9, 2023 | finance.yahoo.com

RxSight, Inc. Reports First Quarter 2023 Financial Results

May 2, 2023 | finance.yahoo.com

Will RxSight, Inc. (RXST) Report Negative Earnings Next Week? What You Should Know

See More Headlines

Receive RXST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RxSight and its competitors with MarketBeat's FREE daily newsletter.

RXST Company Calendar

Last Earnings: 8/07/2023
Today: 10/02/2023
Next Earnings (Estimated): 11/06/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Ophthalmic goods
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RXST
CUSIP: N/A
CIK: 1111485
Web: www.rxsight.com
Phone: 949-521-7830
Fax: N/A
Employees: 292
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $30.50
High Stock Price Forecast: $36.00
Low Stock Price Forecast: $20.00
Forecasted Upside/Downside: +14.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.99)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-66,760,000.00
Net Margins: -88.72%
Pretax Margin: -88.67%
Return on Equity: -48.72%
Return on Assets: -33.79%

Debt

Debt-to-Equity Ratio: 0.12
Current Ratio: 10.89
Quick Ratio: 9.81

Sales & Book Value

Annual Sales: $49.01 million
Price / Sales: 19.45
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.24 per share
Price / Book: 8.26

Miscellaneous

Outstanding Shares: 35,640,000
Free Float: 28,112,000
Market Cap: $953.37 million
Optionable: Not Optionable
Beta: 0.73

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Dr. Ronald M. Kurtz M.D. (Age 60)
Pres, CEO & Director
Comp: $1.03M

Ms. Shelley B. Thunen (Age 69)
CFO & Assistant Sec.
Comp: $651.36k

Dr. Ilya Goldshleger Ph.D. (Age 48)
Chief Operating Officer
Comp: $657.81k

Mr. Eric J. Weinberg (Age 62)
Chief Commercial Officer
Comp: $638.9k

Ms. Rebecca Williston
VP of Accounting & Fin.

Mr. Matt Haller Ph.D.
Chief Technology Officer

Alex Huang
Investor Relations

Mr. Roy Freeman
VP of Marketing

Ms. Caroline Vaughn
VP of HR

Mr. Scott Gaines
Sr. VP of Commercial Operations & Bus. Process

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RXST Stock - Frequently Asked Questions

Should I buy or sell RxSight stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for RxSight in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RXST shares.
View RXST analyst ratings or view top-rated stocks.
What is RxSight's stock price forecast for 2023?: 5 analysts have issued 12-month price objectives for RxSight's stock. Their RXST share price forecasts range from $20.00 to $36.00. On average, they expect the company's stock price to reach $30.50 in the next year. This suggests a possible upside of 14.0% from the stock's current price.
View analysts price targets for RXST or view top-rated stocks among Wall Street analysts.
How have RXST shares performed in 2023?: RxSight's stock was trading at $12.67 at the beginning of the year. Since then, RXST stock has increased by 111.1% and is now trading at $26.75.
View the best growth stocks for 2023 here.
Are investors shorting RxSight?: RxSight saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 1,060,000 shares, a decrease of 24.8% from the August 31st total of 1,410,000 shares. Based on an average daily trading volume, of 462,600 shares, the short-interest ratio is presently 2.3 days. Approximately 3.8% of the shares of the stock are sold short.
View RxSight's Short Interest.
When is RxSight's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our RXST earnings forecast.
How were RxSight's earnings last quarter?: RxSight, Inc. (NASDAQ:RXST) announced its quarterly earnings data on Monday, August, 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.47) by $0.07. The firm had revenue of $20.81 million for the quarter, compared to analyst estimates of $19.21 million. RxSight had a negative net margin of 88.72% and a negative trailing twelve-month return on equity of 48.72%.
What ETF holds RxSight's stock ?: Invesco Dorsey Wright Healthcare Momentum ETF holds 53,792 shares of RXST stock, representing 1.07% of its portfolio.

What guidance has RxSight issued on next quarter's earnings?: RxSight updated its FY 2023 earnings guidance on Monday, August, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $81.00 million-$86.00 million, compared to the consensus revenue estimate of $81.88 million.
When did RxSight IPO?: (RXST) raised $125 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 7,350,000 shares at $16.00-$18.00 per share.
What is RxSight's stock symbol?: RxSight trades on the NASDAQ under the ticker symbol "RXST."
How do I buy shares of RxSight?: Shares of RXST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is RxSight's stock price today?: One share of RXST stock can currently be purchased for approximately $26.75.
How much money does RxSight make?: RxSight (NASDAQ:RXST) has a market capitalization of $953.37 million and generates $49.01 million in revenue each year. The company earns $-66,760,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis.
How many employees does RxSight have?: The company employs 292 workers across the globe.
How can I contact RxSight?: The official website for the company is www.rxsight.com. The company can be reached via phone at 949-521-7830 or via email at ir@rxsight.com.

This page (NASDAQ:RXST) was last updated on 10/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial